Logo image of OVID

OVID THERAPEUTICS INC (OVID) Stock Fundamental Analysis

NASDAQ:OVID - Nasdaq - US6904691010 - Common Stock - Currency: USD

0.5275  -0.09 (-14.71%)

Premarket: 0.5801 +0.05 (+9.97%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to OVID. OVID was compared to 553 industry peers in the Biotechnology industry. OVID scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OVID is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OVID has reported negative net income.
OVID had a negative operating cash flow in the past year.
In the past 5 years OVID reported 4 times negative net income.
OVID had negative operating cash flow in 4 of the past 5 years.
OVID Yearly Net Income VS EBIT VS OCF VS FCFOVID Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

1.2 Ratios

The Return On Assets of OVID (-30.58%) is better than 65.28% of its industry peers.
With a decent Return On Equity value of -42.13%, OVID is doing good in the industry, outperforming 69.26% of the companies in the same industry.
Industry RankSector Rank
ROA -30.58%
ROE -42.13%
ROIC N/A
ROA(3y)-33.31%
ROA(5y)-29.01%
ROE(3y)-46.44%
ROE(5y)-51.69%
ROIC(3y)N/A
ROIC(5y)N/A
OVID Yearly ROA, ROE, ROICOVID Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OVID so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OVID Yearly Profit, Operating, Gross MarginsOVID Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

6

2. Health

2.1 Basic Checks

OVID does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OVID has more shares outstanding
OVID has more shares outstanding than it did 5 years ago.
There is no outstanding debt for OVID. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
OVID Yearly Shares OutstandingOVID Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
OVID Yearly Total Debt VS Total AssetsOVID Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

OVID has an Altman-Z score of -6.15. This is a bad value and indicates that OVID is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.15, OVID is doing worse than 64.01% of the companies in the same industry.
OVID has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.15
ROIC/WACCN/A
WACC9.82%
OVID Yearly LT Debt VS Equity VS FCFOVID Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 4.93 indicates that OVID has no problem at all paying its short term obligations.
OVID has a Current ratio (4.93) which is in line with its industry peers.
OVID has a Quick Ratio of 4.93. This indicates that OVID is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of OVID (4.93) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.93
Quick Ratio 4.93
OVID Yearly Current Assets VS Current LiabilitesOVID Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

OVID shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.05%, which is quite impressive.
The Revenue has grown by 11.93% in the past year. This is quite good.
Measured over the past years, OVID shows a very negative growth in Revenue. The Revenue has been decreasing by -86.05% on average per year.
EPS 1Y (TTM)52.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.65%
Revenue 1Y (TTM)11.93%
Revenue growth 3Y-86.05%
Revenue growth 5YN/A
Sales Q2Q%-12.16%

3.2 Future

OVID is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -28.20% yearly.
Based on estimates for the next years, OVID will show a very strong growth in Revenue. The Revenue will grow by 99.19% on average per year.
EPS Next Y-66.33%
EPS Next 2Y-32.58%
EPS Next 3Y-33.93%
EPS Next 5Y-28.2%
Revenue Next Year-52.39%
Revenue Next 2Y-29.19%
Revenue Next 3Y-30.08%
Revenue Next 5Y99.19%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
OVID Yearly Revenue VS EstimatesOVID Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
OVID Yearly EPS VS EstimatesOVID Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OVID reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OVID is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OVID Price Earnings VS Forward Price EarningsOVID Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OVID Per share dataOVID EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A cheap valuation may be justified as OVID's earnings are expected to decrease with -33.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-32.58%
EPS Next 3Y-33.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OVID!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OVID THERAPEUTICS INC

NASDAQ:OVID (7/28/2025, 8:00:02 PM)

Premarket: 0.5801 +0.05 (+9.97%)

0.5275

-0.09 (-14.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-18 2025-08-18/bmo
Inst Owners55.99%
Inst Owner Change0.63%
Ins Owners5.68%
Ins Owner Change0.62%
Market Cap37.51M
Analysts87.69
Price Target2.93 (455.45%)
Short Float %1.75%
Short Ratio0.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.4%
Min EPS beat(2)-0.43%
Max EPS beat(2)23.22%
EPS beat(4)3
Avg EPS beat(4)44.9%
Min EPS beat(4)-0.43%
Max EPS beat(4)152.99%
EPS beat(8)6
Avg EPS beat(8)-12.52%
EPS beat(12)9
Avg EPS beat(12)-4.63%
EPS beat(16)11
Avg EPS beat(16)-3.44%
Revenue beat(2)1
Avg Revenue beat(2)47.13%
Min Revenue beat(2)-60.64%
Max Revenue beat(2)154.9%
Revenue beat(4)3
Avg Revenue beat(4)81.4%
Min Revenue beat(4)-60.64%
Max Revenue beat(4)154.9%
Revenue beat(8)7
Avg Revenue beat(8)97.9%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8%
PT rev (3m)-10.16%
EPS NQ rev (1m)-3.19%
EPS NQ rev (3m)-18.87%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.26%
Revenue NQ rev (1m)-4.16%
Revenue NQ rev (3m)-9.8%
Revenue NY rev (1m)0%
Revenue NY rev (3m)45.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 68.45
P/FCF N/A
P/OCF N/A
P/B 0.63
P/tB 0.63
EV/EBITDA N/A
EPS(TTM)-0.35
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0.01
BVpS0.83
TBVpS0.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.58%
ROE -42.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.31%
ROA(5y)-29.01%
ROE(3y)-46.44%
ROE(5y)-51.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.98%
Cap/Sales 25.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.93
Quick Ratio 4.93
Altman-Z -6.15
F-Score4
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)110.15%
Cap/Depr(5y)112.76%
Cap/Sales(3y)52.29%
Cap/Sales(5y)32.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.65%
EPS Next Y-66.33%
EPS Next 2Y-32.58%
EPS Next 3Y-33.93%
EPS Next 5Y-28.2%
Revenue 1Y (TTM)11.93%
Revenue growth 3Y-86.05%
Revenue growth 5YN/A
Sales Q2Q%-12.16%
Revenue Next Year-52.39%
Revenue Next 2Y-29.19%
Revenue Next 3Y-30.08%
Revenue Next 5Y99.19%
EBIT growth 1Y7.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.56%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-2.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.98%
OCF growth 3YN/A
OCF growth 5YN/A